Skip to Content

John M. Slopis, M. D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Neurofibromatosis Program, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Neurology, The University of Texas Medical School at Houston, Houston, TX

Education & Training

Degree-Granting Education

1983 The University of Texas Medical School, Houston, TX, MD, Medicine
1979 University of St. Thomas, Houston, TX, BA, Chemistry

Board Certifications

11/1994 American Board of Psychiatry and Neurology with Special Qualifications in Child Neurology, Recertification Date: 8/2004


Institutional Committee Activities

Member, The Neurologic Death Task Force of the ICU Best Practice Committee, 1/2011-present

Honors and Awards

2010-present America's Top Pediatrician, Consumers' Research Council of America

Selected Publications

Peer-Reviewed Original Research Articles

1. Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, Northrup H. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberouos sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs RD 12(3):121-126, 9/2012.
2. Subbiah V, Slopis J, Ketonen L, Hamilton J. Treatment of patients with advanced neurofibromatosis type 2 (NF2) with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 30(5):e64-e68, 2/2012. e-Pub 12/2011.
3. Angelo LS, Wu JY, Meng F, Sun M, Kopetz S, McCutcheon IE, Slopis JM, Kurzrock R. Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways. Molecular Cancer Therapeutics 10(11):2094-2103, 11/2011. e-Pub 9/2011.
4. Pearlman M, Frye R, Butler I, Papanicolaou AC, Castillo E, Slopis J. Patterns of electromagnetic activity recorded from neoplastic tissue. J Neurooncol 105(2):445-449, 11/2011. e-Pub 5/2011. PMID: 21573889.
5. Rokes C, Ketonen LM, Fuller GN, Weinberg J, Slopis JM, Wolff JE. Imaging and spectroscopic findings in meningioangiomatosis. Pediatr Blood Cancer 53(4):672-4, 10/2009. e-Pub 6/2009. PMID: 19544396.
6. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 249(6):1014-22, 6/2009. PMID: 19474676.
7. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 8(5):1157-68, 5/2009. e-Pub 5/5/2009. PMID: 19417153.
8. Koenig MK, Sitton CW, Wang M, Slopis JM. Central nervous system complications of blastic hyperleukocytosis in childhood acute lymphoblastic leukemia: diagnostic and prognostic implications. J Child Neurol 23(11):1347-52, 11/2008. PMID: 18984849.
9. Neville HL, Seymour-Dempsey K, Slopis J, Gill BS, Moore BD, Lally KP, Andrassy RJ. The role of surgery in children with neurofibromatosis. J Pediatr Surg 36(1):25-29, 1/2001. PMID: 11150433.


1. Debnam JM, Ketonen L, Slopis JM, McCutcheon IE, Hamberg LM, Hunter GJ. Multidetector CT Evaluation of the Spine in Patients with Neurofibromatosis Type I. Presented at the American Society of Neuroradiology 45th Annual Meeting. Submitted.


1. OncoLog.

Extensively quoted in "Treating Neurofibromatosis" article in OncoLog, November-December 2009, Vol. 54, No. 11-12

2. Blogs.

1. Extensively quoted in "Go Ahead, Ask: Neurofibromatosis Patient Invites Questions, Makes Friends" article on the February 1, 2011 posting of Cancerwise, a blog on current cancer news located at

2. Responded to questions in "Q&A: Neurofibromatosis and Its Relationship to Cancer" article on the February 1, 2011 posting of Cancerwise, a blog on current cancer news located at



Grant & Contract Support

Title: Topical Rapamycin Therapy to Relieve Cutaneous Manifestations of Tuberous Sclerosis Complex
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Principal Investigator: Mary Kay Koenig, MD
Duration: 9/1/2011 - 8/31/2014

Last updated: 3/13/2015